Omega Diagnostics has received the World Health Organisation (WHO) Prequalification for VISITECT CD4 Advanced Disease test.

The test is a rapid, semi-quantitative lateral flow assay that estimates CD4 protein on the surface of CD4+ T cells in human whole blood.

It is said to be the only currently available handheld lateral flow point-of-care test for identifying the risk of potentially life-threatening opportunistic infections in patients with advanced HIV.

The test can be used in decentralised settings at the point-of-care or primary healthcare level.

As part of the WHO Prequalification, the VISITECT CD4 Advanced Disease test will now be included in the organisation’s list of prequalified in vitro diagnostics (IVD). It is now eligible to participate in the procurement processes of UN agencies.

WHO member states use the WHO list of prequalified IVDs for their respective procurement decisions.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Omega CEO Colin King said: “We are extremely pleased to receive WHO Prequalification on our VISITECT CD4 Advanced Disease test, which has allowed PEPFAR and UN agencies to get the test incorporated into their budgets for 2021, meaning the test can reach more people in those countries most in need.

“This has been an extensive process, and I am proud of the team delivering on such an important milestone for the group in such challenging economic conditions.”

Omega recently secured a supply agreement with Clinton Health Access Initiative to scale up the access of the test to low-income, lower-middle income and upper-middle income countries.

In April, Omega signed a memorandum of understanding (MoU) with three other UK companies to jointly develop and manufacture a Covid-19 point-of-care antibody test.